1. Home
  2. WTF vs SGMT Comparison

WTF vs SGMT Comparison

Compare WTF & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • WTF
  • SGMT
  • Stock Information
  • Founded
  • WTF 1989
  • SGMT 2006
  • Country
  • WTF Hong Kong
  • SGMT United States
  • Employees
  • WTF N/A
  • SGMT N/A
  • Industry
  • WTF
  • SGMT
  • Sector
  • WTF
  • SGMT
  • Exchange
  • WTF NYSE
  • SGMT Nasdaq
  • Market Cap
  • WTF 315.5M
  • SGMT 269.2M
  • IPO Year
  • WTF 2025
  • SGMT 2023
  • Fundamental
  • Price
  • WTF $5.71
  • SGMT $8.22
  • Analyst Decision
  • WTF
  • SGMT Strong Buy
  • Analyst Count
  • WTF 0
  • SGMT 6
  • Target Price
  • WTF N/A
  • SGMT $23.17
  • AVG Volume (30 Days)
  • WTF 98.9K
  • SGMT 3.6M
  • Earning Date
  • WTF 01-01-0001
  • SGMT 08-13-2025
  • Dividend Yield
  • WTF N/A
  • SGMT N/A
  • EPS Growth
  • WTF N/A
  • SGMT N/A
  • EPS
  • WTF 0.04
  • SGMT N/A
  • Revenue
  • WTF $10,508,879.00
  • SGMT N/A
  • Revenue This Year
  • WTF N/A
  • SGMT N/A
  • Revenue Next Year
  • WTF N/A
  • SGMT N/A
  • P/E Ratio
  • WTF $161.00
  • SGMT N/A
  • Revenue Growth
  • WTF 4482.47
  • SGMT N/A
  • 52 Week Low
  • WTF $4.05
  • SGMT $1.73
  • 52 Week High
  • WTF $19.85
  • SGMT $10.43
  • Technical
  • Relative Strength Index (RSI)
  • WTF N/A
  • SGMT 59.75
  • Support Level
  • WTF N/A
  • SGMT $6.56
  • Resistance Level
  • WTF N/A
  • SGMT $10.43
  • Average True Range (ATR)
  • WTF 0.00
  • SGMT 1.36
  • MACD
  • WTF 0.00
  • SGMT -0.07
  • Stochastic Oscillator
  • WTF 0.00
  • SGMT 46.95

About WTF WATON FINANCIAL LIMITED

Waton Financial Ltd is a holding company that operates its business through subsidiaries in the securities brokerage and distribution services, margin financing services, and other ancillary services business; Software licensing and related support services, including licensing of trading platform applications, upgrades and enhancements, maintenance; and other associated services to securities brokers and financial institutions. The group also provided software licensing and related support services, including licensing trading platform applications, and others.

About SGMT Sagimet Biosciences Inc. Series A

Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.

Share on Social Networks: